Policyholders will get unlimited access to Joii Pet Care’s video consultations with UK veterinary surgeons, which usually cost £24 per call.
Pet owners with Asda Money pet insurance will also be able to access Joii Pet Care’s symptom checker, which is designed to help pet owners pinpoint issues from their home.
Paul Hallett, co-founder of Vet-AI, said: “We’re delighted to announce this major partnership, which completely opens up access to professional vet care for thousands of pet parents who will benefit hugely from accessing regular, preventative veterinary care from the comfort of their homes.
“Many pet owners are now facing high vet bills and difficulties accessing in-practice veterinary care.
"Both Markerstudy Broking and Asda Money share our commitment to put animal welfare first, and collectively we’ll ensure more owners have easily accessible choice to receive the very best care for their pets.”
Ceva Animal Health has published video recordings of its second 'Human and Veterinary Crosstalk Symposium on Aldosterone'.
Over 100 world experts in human and veterinary cardiology from 15 different countries attended the symposium, where delegates explored the similarities and differences between human and canine heart failure, and shared the latest research on the harmful effects of aldosterone.
The recordings from this meeting are now available to watch on http://cardiosymposium2011.ceva.com/, where you can also download the full proceedings.
The webinars already available cover subjects like cardiopulmonary resuscitation (CPR), emergency diagnostics and traumatic brain injury, presented by experienced emergency vets Aoife Reid, Liron Levy-Hirsch and Jacqueline Seymour.
More content is due to be added to the library in the coming weeks, including guest webinars from TVM UK on rodenticide and seizure management, and from clinical psychologists Dr Jo Becket and Dr Jess Brown on “thrive, not just survive” and “when stress gets too much”. There will also be a session from ECC specialist Tobias Grave (pictured right) on how to deal with some of the most common pet emergencies.
Tobias will also be on hand to help veterinary surgeons and nurses whose practices use Vets Now for their out-of-hours service with both general advice and a second opinion on potentially complex cases via the new support line.
Tobias said: “Covid-19 is bringing fresh challenges to vets and vet nurses every day. With clinicians seeing a caseload which is mainly emergency and often having to triage patients over the phone or by video consult, it’s never been so important to come together as a profession.
"Both our webinars and our specialist support line for practices who use our service will help equip vet professionals with the skills and knowledge needed to deal with challenging emergencies in practice."
You can find Vets Now’s library of free ECC webinars here.
Chris Jordan, veterinary surgeon at Companion Care vets in Chingford, Essex, is the 500th vet to sign up to the RCVS Certificate in Advanced Veterinary Practice (CertAVP), which was launched in 2007.
Having completed his Professional Development Phase in July, Chris is now working towards a designated certificate in Small Animal Surgery. He said: "The qualification looks well structured and I think it will serve me well whether I continue as a general practitioner or take up a more surgery-focused role."
Freda Andrews, RCVS Head of Education, said: "The modular approach means vets have much more choice about how and what they study. All certificates show the modules assessed, so that it is easy for veterinary employers to see what a vet has studied, whether or not they have taken a 'named' certificate."
To gain the qualification, vets must first enrol with the RCVS, and then enter for assessment in a combination of core and optional modules through an RCVS-accredited institution. Vets then have ten years in which to complete the qualification. Study can be entirely self-directed; however, there are a number of courses on offer from educational institutions to help vets prepare for assessment. Distance and online learning is a feature of many of these courses.
Vets who want to pursue an area of interest for continuing professional development without working towards any certificate, can equally enrol for assessment in any of the 85 individual modules currently available; this is done directly through the institutions offering assessment and does not need enrolment with the RCVS. Full details of enrolment and module requirements can be found at www.rcvs.org.uk/modcerts
There's a complimentary counter top unit and pillow packs to help veterinary surgeons and nurses communicate the benefits of probiotics to clients. The unit can hold a cat and dog 30 sachet box of Purina Pro Plan FortiFlora from practice stock and the pillow packs can be used to dispense single sachets, so the client can trial the product with their pet at home.
At the same time, the company is encouraging vets and nurses to look at the evidence behind the probiotics they recommend. Although carried out a while ago now (2003 and 2011), two studies have shown that other diets claiming to contain probiotics generally did not meet the label claim when evaluated1,2.
Libby Sheridan, MVB MRCVS, Purina Veterinary Technical Affairs Manager, UK & Ireland says the efficacy of probiotics is thought to be strain-specific3 and recommends that clinicians critically assess the evidence for the particular strain and preparation of probiotics stocked or used.
Libby said: "The quality and efficacy of probiotics can vary and while in some cases there is strong evidence for efficacy in the targeted species, for others, the evidence is scant. Having experienced it myself, I know it's not always easy when working in a busy practice to take the time to ensure the evidence is there, but the studies back up that we should assess these things carefully before making a robust recommendation to our clients."
Most of the probiotics commercially available to veterinary professionals use the lactic acid bacterium Enterococcus faecium.
The particular strain and preparation of any probiotic will affect its ability to reach the large intestine, the expected site of action, intact. The evidence for the SF68 strain of Enterococcus faecium has been validated in a number of studies4-11 over recent years. Proven benefits of the SF68 strain include those focused on the gastrointestinal system where it supports canine and feline intestinal health and microflora balance and those with wider implications, such as support for a healthy immune system.
To obtain a unit or discuss the science, contact your Purina Veterinary Nutrition Partner or telephone the Purina Veterinary Nutrition Team on 0800 212161 quoting code VETPRESS.
References
55 veterinary surgeons took part in the survey, which also found that only 37% of clinicians use FNA and cytology when investigating a suspected lipoma.
According to the survey, the biggest barriers to further investigations of lumps and bumps were cost (50%), short consult time (23%) and confidence in results (20%).
HT Vista, which earlier this year launched a cancer screening device for dogs which uses heat diffusion technology and AI to differentiate between benign skin masses and other tumours, is urging more practising vets to use an accurate screening process for early detection of malignant masses.
Dr. Gillian Dank, Board Certified Oncologist and Chief Veterinary Officer at HTVet, said: “There is no way to know that a mass is a lipoma based on palpation alone.
"The fact that a mass is subcutaneous, soft and circumscribed is not exclusive to lipoma and it could be a number of things including a mast cell tumour or sarcoma.
"On average a veterinary practice sees over 500 dermal and subcutaneous masses each year.
"We know anecdotally, and surveys like this confirm, that not every mass is aspirated – and that is why there is need for the HT Vista screening device.
"Every mass that comes in should be properly examined.”
“It’s interesting to see that the more experienced a clinician is, the less confident they are in diagnosing from palpation and this shows us that with experience we understand that our hands are not enough.”
Liron Levy-Hirsch, Managing Director of HT Vista, said: “The survey showed that vets are conscious of the cost to clients, and also feel pressured due to time.
"We have developed the HT Vista to complement FNA and cytology, and hope clinicians find it a useful tool.
"Firstly, it is quick and affordable to scan, and for those masses that are benign it removes the need for unnecessary FNA’s.
"Secondly, vets are often wary of cost, however if a mass is scanned and the results indicate that further investigation is needed, there is more rationale to spend the extra money to get the cytology results.
"Finally, the device can offer complete confidence that malignancies are not being missed, and if a mass is malignant a prompt treatment plan can be initiated.”
https://www.vetreport.net/wp-content/uploads/2023/08/Lump-and-Bump-Survey-2023FINAL.pdf
https://ht-vista.uk
Vétoquinol has announced the return of Navilox powder (isoxsuprine hydrochloride), the only medication specifically licensed in the UK for use in cases of navicular disease in horses.
Navicular disease is a chronic degenerative condition of the navicular bone and associated structures. It is a syndrome with a complex pathogenesis which combines various underlying causes. Vétoquinol says it is a common cause of lameness in the middle aged riding horse.
Robert Simpson, Navilox Product Manager said: "Navilox has been sorely missed by equine vets in the UK which is why I am thrilled to be able to announce that it is available again."
To order Navilox powder, call Vétoquinol on 01280 825424 or contact your wholesaler directly.
Sarah, who practices at Southfields Veterinary Specialists, was already a European and Royal College Specialist in oncology. Now, after studying for a year and passing the European College of Veterinary Internal Medicine (ECVIM) exams this autumn, she has now been recognised as a European Specialist in radiation oncology as well.
Sarah said: "I intend to use my experience to grow the radiation and oncology service at Southfields and, with the benefit of our new linear accelerator and state-of-the-art hospital, deliver the most advanced treatment options for our veterinary patients.
"I also intend to use my experience and expertise to contribute to the further development of radiation oncology as a specialist qualification in Europe."
Congratulations Sarah!
Urging vets to 'get off their backsides and respond to a VMD consultation' on the introduction of a new POM-EA category (Vet Times, 19th October) is premature.
Contrary to the report, the VMD has not yet launched a formal consultation.
Jo Cawthorne from the VMD said: "In fact, we've only launched an informal consultation on a concept note amongst a small group of key stakeholders from the RCVS, BVA, RPSGB, AMTRA, AHDA and NOAH, in order to decide whether this is a viable idea and merits a formal consultation."
She added: "There is no need for vets to respond to a consultation which doesn't yet exist. If there is a formal consultation, it will be announced formally on our website and everyone will be given the opportunity to respond."
The company says that the composition and dosage of the new product has been optimised for maximum efficacy 1, 2. It offers three-five days on-label treatment options and does not need to be stored in a fridge.
According to Boehringer, the 600mg dose results in a concentration well above MICs for Strep. uberis and Staph. aureus for 24 hours, even after milking, which means it needs to be administered once a day1. In addition, its formulation enables optimum distribution of penicillin throughout the udder2.
Kath Aplin veterinary adviser at Boehringer Ingelheim said: "Traditionally, in the UK, we have favoured broad spectrum mastitis therapy as our first line approach, however in many other European countries, including The Netherlands, Belgium, Sweden and Denmark, penicillin is the treatment of choice.
"For farms with a mixed or unknown mastitis pattern, the traditional broad spectrum approach to mastitis therapy makes sense. However, many vets now have a good knowledge of common mastitis pathogens on clients’ farms and, for those where gram +ve pathogens predominate, penicillin as a first line treatment is well worth considering."
In a field trial assessing the prevalence of mastitis-causing pathogens and clinical cure rates after treatment with Ubropen3, mild and moderate cases of mastitis were treated for three to five days, with the causal pathogen being unknown at the time of treatment.
Kath said: “In 80% of cases of grade one or two clinical mastitis, the causative pathogen was found to be gram +ve and, following treatment with Ubropen, the overall clinical cure rate was 81%".
Ubropen is now available from the usual veterinary wholesalers in boxes of 20 tubes.
References:
‘Is neutering dogs doing more harm than good?’ (BVA Congress Theatre, Thursday 16th November 2023 at 10.30am), will explore the latest research into the science of neutering and its impact on dog health and welfare, particularly on behaviour, and will also consider the role of non-surgical alternatives.
The session will be chaired by BVA President Dr Anna Judson, joined by:
The BVA says statistics from its Voice of the Veterinary Profession survey show that among clients who chose to neuter their dogs last year, only 6% picked non-surgical options.
Awareness of these options is low, with vets reporting that 9% of their clients had requested information about non-surgical options when considering neutering, such as sustained-release implants to suppress testosterone production in male dogs.
Among those who considered non-surgical options, clients cited the cost and need for repeat treatments as their main concerns (mentioned by 67% and 58% of vets, respectively), followed by individual variation in the effect and duration of non-surgical alternatives (22% of vets).
Anna said: “Canine neutering is a firmly established part of preventive pet healthcare in the UK, but it is also very much a live discussion within the veterinary profession, with a healthy ongoing debate around its merits and risks, based on evolving evidence.
"BVA’s survey shows low awareness among clients about all available neutering options for their pets, with only a tiny percentage choosing to go down the non-surgical route.
“Our BVA Congress discussion will offer vet professionals in small animal practice insight into the latest research on neutering, including potential longer-term impacts on a dog’s health and behaviour, and views on what that might mean for how vets discuss neutering options with clients.
"The panellists will also share useful tips on how to deal with clients’ questions about surgical and non-surgical options for their pets.”
https://bvajournals.onlinelibrary.wiley.com/toc/20427670/2023/193/S1
First you need to complete your VetSurgeon Profile, in particular the last four sections: "Qualified at", "Interests", "Interested in collaborating on" (aka goals) and "Memberships".
Then visit VetSurgeon Connect and click the button marked "Share My Location". This will activate the map beneath, allowing you to see local colleagues with common interests. It will also pin you on the map, but only in front of logged in members of the site with whom you have a common interest.
One area of common interest is the connection between general practitioners and referral practitioners. Referral practitioners who have shared their location are pinned on the map and can be seen by general practitioners (who can also filter them by discipline).
It is hoped that this will help create a more vibrant referral marketplace, as it offers referral practitioners who do not have big marketing budgets a way to connect with local general practitioners.
The system also matches VetSurgeon members by a number of other criteria. So for example, if you specify 'Qualified at' in your profile, it will display anyone else who went to the same vet school. If you display a leisure interest like cycling in your profile, it'll display other vets in your area who also like cycling.
If you display a clinical interest, such as oncology, it'll show you others in the area with the same interest.
The same thing happens with 'Interested in collaborating on', which connects you with others working towards the same goals, which can be business goals like practice ownership or a learning goals, such as CPD or being a mentor/mentee.
Lastly, if you specify your membership of a special interest veterinary association, the system will show you other members who are in your area.
VetSurgeon Editor Arlo Guthrie said: "It’s kind of a professional matchmaking service designed to make it easier than ever before for veterinary surgeons and others to hook up and collaborate on all sorts of different things.
"It may be you think you know everyone you need to know in your area already. But so often we think we know people, then find out we didn’t know about a shared passion for something, whether it be a professional or a leisure interest. Indeed, I think the system could be just as useful in connecting members to go on a bike ride together as it is to help them collaborate on CPD or on achieving additional qualifications."
Chris Taylor from Swann-Morton said: "We are really pleased to be part of this initiative which should help to bring the veterinary community closer together through shared experiences and knowledge."
Arlo added: "I’m very grateful for Swann Morton’s support. If you are too, you can show it by visiting the company's website and having a quick browse of the latest products in its veterinary range at www.swann-morton.com."
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
Reference
Mark, an Advanced Practitioner in Zoological Medicine, is well known in the profession, having lectured in the UK and internationally, as well as having numerous articles on exotic topics published in peer reviewed veterinary journals.
Mark said: “I’m really pleased to be joining Pennard Vets, which has seven sites across Kent, and is owned by its employees, which made it a particularly attractive place to join, as I now also own a stake in the business and can help shape the future of it. I can’t wait to meet our clients and their pets and hope to make a real difference to their lives.”
Andy Green, Director at Pennard Vets, said: “Mark is the most qualified vet in the South East of England working in exotics, and we are delighted he is bringing so much experience to Pennard Vets.
"We hope to become the go-to practice for all exotic pets in the South-East and believe that our new and existing clients will all benefit from Mark’s unique and thoughtful approach to veterinary care.”
www.pennardvets.com
Hill's Pet Nutrition is to launch Prescription Diet y/d Feline for the nutritional management of feline hyperthyroidism in May.
According to the company, hyperthyroidism is the most commonly diagnosed endocrinopathy in cats globally, and is thought to affect around 10% of cats over the age of nine in the UK.1.
Prescription Diet y/d Feline is clinically proven to manage thyroid health in three weeks3 and gives vets a new management modality to address the needs of hyperthyroid cats. Hill's says that the new product is essentially a low iodine food; production of thyroid hormones T3 and T4 require iodine molecules, so limiting the amount of dietary iodine reduces the amount of thyroid hormones produced and released by the thyroid gland.
Hill's highlights three key studies in peer reviewed veterinary journals which the company says demonstrates the efficacy of y/d.2-4 The research identified that limiting the amount of iodine consumed resulted in a lowering of T4 (serum total thyroxine) to normal levels, with significant reductions in just 3 weeks.2
Hill's says that the availabillity of nutrition as a treatment option marks a major step forward from invasive surgery, treatment with radioactive iodine - which is available in only a few centres in the UK - or pilling, which can prove to be particularly difficult for some pet owners. The company adds that a gradual transition to y/d is also an option where medical treatment is proving problematic.
Cats with hyperthyroidism have a multisystemic disease and concurrent problems can develop, such as hypertension, cardiovascular abnormalities and recurrent urinary infections. Additionally, many older cats with hyperthyroidism have concurrent renal dysfunction, which is often 'unmasked' when the hypertension is bought under control. Therefore, y/d also has controlled levels of phosphorus and low sodium for renal and circulatory health, reduced magnesium and moderate urine pH target for urinary health and taurine and carnitine for heart health.
Hill's Prescription Diet y/d Feline will be available from 1st May.
For more information, visit www.catthyroidhealth.com
1. Symes H, Winter 2008/2009. Feline hyperthyroidism. The Endocrinologist. Issue 90, pp 10-12. Symes H, Winter 2008/2009. Feline hyperthyroidism. The Endocrinologist. Issue 90, pp 10-12.2. Controlled level of dietary iodine normalizes serum total thyroxine in cats with naturally occurring hyperthyroidism Yu S, Wedekind KJ, Burris PA, et al. J Vet Intern Med 2011;25:683-684 (abstract).3. Titration of dietary iodine for reducing serum thyroxine concentrations in newly diagnosed hyperthyroid cats Melendez LD, Yamka RM, Forrester SD, et al. J Vet Intern Med 2011;25:683 (abstract).4. Titration of dietary iodine for maintaining normal serum thyroxine concentrations in hyperthyroid cats Melendez LD, Yamka RM, Burris PA. J Vet Intern Med 2011;25:683 (abstract).
The Pitpat was designed in Cambridge, launched in 2016 and is now the leading dog activity monitor on the market, with over 50,000 sold.
I was invited to review the Pitpat by one of the company's non-executive directors, Myra Forster-van Hijfte FRCVS, a European and RCVS Specialist in Small Animal Medicine who was also one of the angel investors.
I wasn't convinced that this was something every dog owner would want to use regularly. You'd have to be a bit obsessed to be routinely reviewing the activity levels of a perfectly fit young dog. But I think there is real potential for it to add value to veterinary nurses' obesity clinics and also to measure a response to treatment for things like osteoarthritis (OA). As such, it is perhaps something for practices to consider buying for themselves, and then loaning it out to the owners of dogs on a weight loss programme or which are getting treatment for OA.
Myra said: "PitPat gives an objective measurement of the actual activity the dog has done and the app gives the owner tailored advice (based on breed, age and sex of the dog) on how much exercise their dog should be doing and an estimate of daily calories their dog has burnt. This will help owners keep their dogs fit and healthy and in the correct body condition.
"PitPat is useful in weight management clinics by improving owner engagement through the associated weight app. Encouraging exercise also provides the owner with a positive contribution towards weight management.
"Monitoring activity pre- and post treatment, for instance dogs with osteoarthritis on NSAID's, provides vet and owner with an objective measure of whether treatment is effective or not."
You can watch the full review here. If you're interested in technology that is designed to make life easier, do subscribe to the channel!
For more information about Pitpat, visit: https://www.pitpat.com/. Veterinary practices that want to buy a Pitpat for use with their clients will get a trade discount. Contact the company for more details.
Virbac has been granted a Limited Marketing Authorisation in the UK for its Gudair vaccine, indicated for the active immunisation of sheep and goats against Mycobacterium avium subspecies paratuberculosis (MAP).
MAP is the causal organism for Johne's Disease, a chronic infection of the intestinal system for which there is no cure.
According to Virbac, Johne's Disease enters most flocks following the introduction of infected stock, often breeding rams, bought at markets without checks on disease provenance. It is then spread by the faeces of often apparently healthy animals but which can contain huge numbers of MAP. The main clinical sign is a thin ewe resulting in poor productivity followed by inevitable death. It can be passed between sheep and cattle.
Ovine Johne's Disease (OJD) in sheep is widespread in Australia where annual death rates of up to 17% have been seen in infected flocks. Virbac says that trials conducted there have demonstrated that vaccination with Gudair can reduce the number of deaths due to OJD by 90% and reduce the numbers of OJD-causing organisms excreted in sheep faeces by 90%.
Ken Sibley MRCVS, Technical Advisor at Virbac says that the number of infected flocks in the UK is unknown and the disease often remains undiagnosed: "Johne's Disease can be a significant cause of loss in infected sheep flocks because of reduced productivity and high culling rates. Vaccination provides the only possible assurance when sourcing sheep from potentially infected flocks and will help to reduce losses from the disease should a farmer inadvertently introduce sheep into an infected flock.
"Lambs identified as replacements should generally be vaccinated between 4 and 16 weeks of age, subcutaneously behind the ear. Sheep over 16 weeks of age can also be vaccinated as this will reduce shedding of organisms in infected animals while bought-in replacements can be vaccinated on arrival at the farm. Sheep require only one vaccination for their lifetime.
"Following its success in Australia, we are delighted to be able to offer Gudair to veterinary surgeons in the UK."
For further information, contact your Virbac territory manager or call: 01359 243243
The company says the new product has been 10 years in development and uses 'Soft Mist' technology - developed originally for human use by its pharma business - to deliver medication deep into the horse's lungs.
The active ingredient in the Aservo EquiHaler is ciclesonide, a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
The Aservo EquiHaler does not use a propellant, so it does not contribute to greenhouse gas emissions. Boehringer also highlights that it is made from up to 50% recycled materials. In April, the product was awarded a Red Dot Design Award.
Dr Marc Laemmer, Head of Equine in UK & Ireland said: "It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.
"We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available. Out team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require."
Vetoquinol UK Limited has launched Ceftiocyl: a ready-to-use formulation containing 50mg/ml ceftiofur for use in cattle and pigs.
In cattle, Ceftiocyl can be used for the treatment of respiratory disease, acute interdigital necrobacillosis and acute post-partum metritis. In pigs, Ceftiocyl is licensed for the treatment of respiratory disease. Ceftiocyl has the added benefit of traceability stickers which are attached to each vial making it easier and quicker to record and monitor on-farm usage.
Susan Mitchell, Large Animal Product Manager at Vetoquinol UK Ltd said, 'We are delighted to be expanding our large animal anti infective range offering. Marbocyl 10% has been used for acute mastitis in the dairy sector for many years, the addition of Ceftiocyl to our portfolio enables us to provide a cost-effective treatment for both metritis and lameness.'
1. Willshire, J.A. & Bell, N, J. (2009) An economic review of cattle lameness. Cattle Practice 17, 136-141.
The reasons are: above average increases in veterinary salaries, advances in veterinary medicine which mean practices can now offer ever more complex but expensive treatments, veterinary practices becoming more business-focused and now charging fair prices for services that they have in the past subsidised, and the cost of providing out-of-hours care.
One reason for the increase in veterinary salaries is the fact that historically veterinary surgeons and especially nurses have been relatively badly paid, although for vets that was always mitigated by the expectation of practice ownership later in their career, something which is no longer a realistic prospect for many.
Veterinary salaries have also been driven higher by the reduction in EU vets coming to work in the UK post-Brexit, although the report shows that UK trained vets and vets from the rest of the world are starting to pick up the slack.
The BVA report says it recognises that it is 'challenging' for clients to accept that rising bills are in part because of increased salaries, but they need to increase further still, pointing to the fact that NHS consultants earn around £100K per annum after four years, whilst vets earn around half that.
The submission also points to developments in veterinary medicine and technology which allow for far better standards of care, but which come at increased cost, notably in advanced imaging, dental work and laboratory services which increasingly involves specialist input.
The BVA also highlights the fact that veterinary practices have become more business savvy, especially since the 1997 decision by the RCVS to allow people and organisations other than veterinary surgeons to own practices.
With that came an influx of business skills and a prioritisation of financial considerations.
Lastly, the report points to the ongoing burden of providing out-of-hours care.
Unlike in most European countries, British vets must provide 24 hour emergency first aid and pain relief to animals, the costs of which have increased considerably as practices which used to provide the service in house at a loss, have increasingly opted to outsource it to veterinary service providers which charge commercially realistic prices.
The submission also discusses the cost of prescriptions, noting how important it is that veterinary practices are able to charge for the time and work it takes to issue a prescription, which despite an above-inflation increase, still only costs around £18.
Finally, the BVA addressed the issue of transparency over practice ownership, saying that whilst it is not aware of any data concerning whether pet owners select a practice based on its ownership, it nevertheless "supports the principle of improved transparency of ownership to help increase customer awareness and enable consumers to make an informed choice".
British Veterinary Association President Anna Judson said: “In our submission to the CMA, we have explained the complex challenges facing the profession, alongside highlighting the value of veterinary care.
"The CMA’s review will provide valuable insights, but it is essential that any recommendations are informed with full knowledge and understanding of today’s veterinary landscape and the pressures the profession is operating under, including workforce shortages.”
COMMENT
In all, the submission seems a detailed and fair representation of the reasons for increasing veterinary costs, although there is no mention of the impact of the increasing regulatory burden (such as the cascade), other than, ironically, the need for more regulation at a practice level, as well as of individuals.
It will be very interesting to see what the Competition and Market Authority concludes.
After all, there is no reason whatsoever why veterinary practices shouldn't charge a price which reflects the costs of providing the service, or that veterinary professionals should not be paid reasonably for their knowledge, skills and experience.
The problem is that as the industry has started to charge a commercially viable rate for an increasingly higher standard of more advanced care, so the true cost of providing that care has become clear.
Maybe the industry is in danger of trying to sell a Rolls Royce service to marketplace of people who either can't afford or don't want to spend more than the cost of a Ford Focus.
If that is true, the only logical conclusion is that either society will have to accept that pet ownership is a luxury for a smaller group of people who can afford it, or the industry will have to adapt its offering, in other words offer a lower level of cheaper care in order that more people can experience the joys of pet ownership.
The latter of those will be ideologically challenging for a profession bound by its oath that "my constant endeavour will be to ensure the health and welfare of animals committed to my care", not to mention pet owners who often want the best that the profession can offer, despite not always having the wherewithal to pay for it.
https://www.bva.co.uk/media/5459/submission-to-cma-oct-2023.pdf
Amanda Boag, RCVS President, said: "We understand that this is a concerning situation for many in the profession who are worried about the impact of the shortage of isoflurane on both elective and emergency operations.
"We are also concerned to hear that some vets are worried that they may be disciplined by the RCVS for clinical decisions and outcomes that may arise from the shortage, and so we are keen to stress that we understand that members of the profession can only do their best under the circumstances presented to them and that, provided they can clinically justify the decisions they have made, keep detailed notes, gain informed consent and follow the prescribing rules, then there is very unlikely to be an issue of professional misconduct."
If you have questions about the shortage in relation to the Code of Professional Conduct and its supporting guidance, you can contact the RCVS Standards and Advice Team on 020 7202 0789 or advice@rcvs.org.uk.
For further information about the shortage and alternative sources and products, the RCVS recommends visiting the Veterinary Medicines Directorate website: www.gov.uk/government/organisations/veterinary-medicines-directorate.
Euthasol vet is presented as a clear blue liquid, licensed for intravenous, intracardial and intraperitoneal usage. A dose of 140 mg/kg (equivalent to 0.35 ml/kg) is considered sufficient for all licensed routes of administration.
Euthasol vet comes in vials of 100ml and has a 28 day broached shelf life.
Dechra Brand Manager Claire Morgan said: "Choosing the correct product for euthanasia is vital for veterinary professionals and Euthasol vet offers a highly effective solution.
"The intravenous route of administration should be the route of choice. Where intravenous administration is impossible, the product may be administered via the intracardiac route in all named species.
"Euthasol's versatility in terms of the range of species in which it is licensed for use, coupled with its 400 mg/ml concentration, is set to make it a popular choice in practice."
For more information, visit www.dechra.co.uk
Bought By Many is a company which, until now, has been using technology and data to find the best value insurance cover for pet owners whose needs are not being met. It claims to have helped 265,000 members to get better deals from existing pet insurance providers in this way.
However, in response to 40,000 pieces of customer feedback, it has now launched its own policies.
The company says that common frustrations with existing policies included: premiums that jump after the first year of cover and continue to increase over the life of a pet; customers receiving no benefit from pet insurance if they do not need to claim; and not being able to switch pet insurers and maintain cover for a pre-existing medical condition.
As a result, Bought By Many has launched three new insurance products which it says include features that no other insurer currently offers:
The company also offers 'Value', 'Regular', and 'Complete' conventional pet insurance products. These, it says, also respond to member feedback – for example, by offering the option of a zero excess or dental cover on certain policies.
Bought By Many has also launched a low-cost Liability Only policy for dog owners that starts at £10 a year.
Steven Mendel, Co-founder and CEO of Bought By Many said: "When we started Bought By Many, we wanted to transform the customer experience of insurance, helping people find the right cover for their unique needs. Our social and digital model allowed us to gather a unique set of data that showed consumers see significant gaps in the insurance currently available for cat and dog owners. These insights led to us creating our own pet insurance product range."
APPA is an oral, patented, fixed-dose combination of two synthetic secondary metabolites of plant origin, apocynin and paenol.
Under the terms of the agreement, AKL’s unnamed partner will fund a study in dogs with naturally occurring OA. The study will compare the efficacy and efficacy duration of APPA with the current standard of care for treating canine OA: non-steroidal anti-inflammatory drugs.
David Miles, AKLRD CEO, said: “Just like humans, millions of dogs suffer intolerable pain and disability because of OA and the current treatments just aren’t as effective or as well tolerated as they need to be. We already know from previous canine studies that APPA reduces pain and has an excellent tolerability profile but this exciting new partnership will allow us to go one stage further and assess sustainability of response.”
The randomised study will assess pain and duration of response as the primary endpoint. Secondary endpoint assessment will include adverse events, quality of life, pharmacokinetics analysis and biomarkers that may enable potential identification of factors predictive of response at treatment onset, or that correlate with response magnitude.
Two separate studies on dogs have already been carried out by researchers at the University of Vienna. The first, an 11-week cross-over study of 32 canines diagnosed with established, naturally occurring OA, showed that APPA provides significant symptom relief in clinical canine OA1.
A follow-up, five-week study of 60 dogs with OA compared APPA to the standard of care drug, meloxicam. It concluded that daily oral administration of APPA was effective as a stand-alone alternative to NSAIDs in dogs with naturally occurring OA. Significant benefits were also seen for APPA over meloxicam in orthopaedic examination as well as in lameness and function scores2.
The results will inform the pivotal clinical trial design and AKL says its working assumption is that a 26-week field study would complete the regulatory requirements for commercialisation.
If the study and future testing is successful, AKL estimates that APPA would be well placed to capture a significant share of the global canine OA market, which is estimated to be worth $3billion by 20283.
The study1, which was conducted by surgery resident Dr Charlie Brincin at Highcroft Veterinary Group (soon to be Bristol Vet Specialists) and orthopaedic surgeon Dr Matt Matiasovic at Manchester Vet Specialists, looked at the records of 825 dogs that had been treated surgically for unilateral MPL at 10 referral centres, and then had a planned follow-up visit, including radiographs.
The frequency of, and reasons for, changes in further recovery recommendations were investigated.
The findings demonstrated that if the dog made an uneventful2 recovery after surgery, was presented without owner concern, and if no abnormality was found on physical examination, then radiographic findings only led to a change in recommendation in 3% (13/432) of these dogs.
Researchers say that this reflects similar research on the influence of follow-up radiographs in human medicine, and those of previous veterinary studies on post-operative radiographs, following uncomplicated tibial plateau leveling osteotomy (TPLO). These particular studies3,4 showed radiography had an impact on post-operative management in just 2%-3.8% of cases.
As a result of the MPL and TPLO studies, Highcroft Veterinary Referrals and Manchester Veterinary Specialists will no longer systematically perform follow-up radiographs on their patients, unless justified clinically.
Charlie said: “Radiographs are not without additional costs or risks - including radiation exposure, sedation-associated risks and strain on veterinary staff.
"Radiographic intervention should be clinically justified and our study suggests that if the dog had an uneventful recovery and is presented without owner or clinician raised concern, then repeat radiographs might not be necessary.
"This study also highlights the value of a thorough owner history and clinical examination for clinical decision-making when re-examining dogs following this orthopaedic surgery.”
The MPL study also evaluated factors which significantly increased the risk of finding radiographic abnormalities at routine follow-up, and those which led to a change in post-operative recommendation.
Lameness, administration of analgesia at follow-up, and history of unplanned visits prior to routine re-examination were associated with increased odds of a change in postoperative plan (P < 0.001).
In the absence of owner and clinician concerns, the odds of having a change in convalescence plans were not different, whether or not isolated radiographic abnormalities were present (P = 0.641).